GlassScriptPhysician profile
Ahmed G Elsayed
NPI 1528221827
$8,145.17
in general payments reported to CMS, 2019-2025
72 companies · $1,142 in 2025
The $1,142 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $524 · 2021: $987 · 2022: $1,532 · 2023: $1,464 · 2024: $1,483 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.12 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $570.73 | 2019-2025 | |
| Celgene Corporation | $541.44 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genentech USA, INC. | $487.72 | 2019-2025 | Perjeta, Tecentriq, Phesgo |
| Janssen Biotech, INC. | $480.85 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $380.06 | 2019-2023 | Keytruda |
| Astellas Pharma US INC | $365.26 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Astrazeneca Pharmaceuticals LP | $363.33 | 2019-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $315.51 | 2020-2025 | Enhertu, Vanflyta, Datroway |
| Incyte Corporation | $314.02 | 2019-2024 | Pemazyre, Jakafi, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $260.79 | 2019-2025 | Opdualag, Reblozyl |
| Pfizer INC. | $249.47 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.70 | 2019-2025 | Fruzaqla |
| Seagen INC. | $198.09 | 2019-2023 | Padcev, Tukysa |
| Abbvie INC. | $196.31 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $184.51 | 2022-2024 | Clonoseq |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $172.62 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.73 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $151.91 | 2022-2023 | Xarelto |
| Eisai INC. | $148.97 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.40 | 2019-2025 | |
| G1 Therapeutics, INC. | $126.10 | 2022-2023 | Cosela |
| Blueprint Medicines Corporation | $123.01 | 2020-2024 | Ayvakit |
| Pharmacyclics LLC, An Abbvie Company | $116.36 | 2019-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $104.07 | 2021-2025 | Ojjaara, Blenrep |
| Karyopharm Therapeutics INC. | $88.76 | 2022-2025 | Xpovio |
| Amgen INC. | $84.30 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Rigel Pharmaceuticals, INC. | $82.42 | 2020-2024 | Tavalisse, Rezlidhia |
| Jazz Pharmaceuticals INC. | $81.01 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $74.86 | 2022-2024 | Libtayo |
| Sobi, INC | $74.61 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $69.46 | 2019-2024 | Ultomiris |
| Tersera Therapeutics LLC | $60.94 | 2021-2024 | Xermelo, Zoladex |
| Beigene USA, INC. | $60.64 | 2021-2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $58.40 | 2021-2025 | |
| Array Biopharma INC | $54.43 | 2020-2025 | Mektovi, Lorbrena, Xalkori |
| Epizyme, INC. | $46.18 | 2021-2022 | |
| Taiho Oncology, INC. | $45.25 | 2021-2025 | |
| Foundation Medicine, INC. | $44.73 | 2021-2023 | Foundationone Cdx |
| Pharmaessentia USA Corporation | $44.67 | 2022-2025 | Besremi |
| Stemline Therapeutics INC. | $44.42 | 2024-2025 | Orserdu |
| Servier Pharmaceuticals LLC | $42.37 | 2023-2024 | |
| Emd Serono, INC. | $41.29 | 2023 | Tepmetko |
| Shield Therapeutics INC | $41.12 | 2023-2025 | Accrufer |
| Tempus Ai, INC | $40.35 | 2024-2025 | Xt Cdx |
| Amag Pharmaceuticals, INC. | $40.27 | 2021-2022 | |
| Morphosys, US INC. | $36.00 | 2022-2023 | Monjuvi |
| Recordati_rare_diseases_inc. | $35.87 | 2023-2024 | Sylvant |
| Pharmacosmos Therapeutics INC. | $34.94 | 2024-2025 | Cosela, Monoferric |
| Kyowa Kirin, INC. | $32.21 | 2019-2025 | |
| Puma Biotechnology, INC. | $26.92 | 2020-2021 | |
| Cerus Corporation | $25.16 | 2024 | Intercept Blood System For Platelets |
| Acceleron Pharma, INC. | $22.76 | 2021 | |
| Blue Earth Diagnostics | $22.58 | 2025 | Posluma |
| Cti Biopharma Corp. | $20.16 | 2023 | Vonjo |
| Acrotech Biopharma INC. | $19.96 | 2024 | Beleodaq |
| Tesaro, INC. | $19.30 | 2019 | |
| Geron Corporation | $19.00 | 2024 | Rytelo |
| Novocure INC. | $18.72 | 2024 | Optune |
| Sun Pharmaceutical Industries INC. | $18.34 | 2022 | |
| Exelixis INC. | $17.82 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.76 | 2023 | |
| Lilly USA, LLC | $17.12 | 2020 | |
| Dendreon Pharmaceuticals LLC | $16.84 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.26 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.75 | 2022 | |
| Pharmaand Gmbh | $15.41 | 2025 | Rubraca |
| Tolmar, INC. | $15.41 | 2025 | Rubraca |
| Shionogi INC | $15.37 | 2019 | |
| Eusa Pharma (US) LLC | $14.60 | 2021 | |
| Deciphera Pharmaceuticals INC. | $14.16 | 2023 | Qinlock |
| Organon LLC | $12.39 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Elsayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.